Extracorporeal photopheresis as a therapy for autoimmune diseases
- 26 December 2014
- journal article
- research article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 30 (4) , 224-237
Abstract
Systemic autoimmune diseases (AID) have multiorgan, heterogeneous clinical presentations and are characterized by dysregulation of the immune system, immunodeficiency, irreversible organ damage and increased morbidity and mortality. Preventing or decreasing flares of AID correlate with durable disease control, significant reduction of inflammation and prevention of disability or therapy‐related toxicity. There is an urgent need for better treatment of severe, therapy‐refractory AID. Extracorporeal photopheresis (ECP) is a cell‐based immunomodulatory treatment which has been extensively used in variety of autoimmune disorders for the last two decades. ECP treatment is FDA approved for the treatment of cutaneous T‐cell lymphoma (CTCL) with particularly promising results seen in graft‐versus‐host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Prolonged therapy is safe, well tolerated and allows reduction of systemic immunosuppression in therapy‐refractory patients. Both clinical and experimental evidence suggest that ECP mechanism of action is characterized by apoptosis and phagocytosis of activated cells by antigen‐presenting cells (APC), secretion of anti‐inflammatory cytokines and stimulation of regulatory T cells (Tregs). The focus of this paper is to review the current evidence of ECP use in the treatment of AID. Here, we summarize the experience of nine major AID from 65 published reports. The key findings demonstrate substantial evidence of ECP feasibility, safety and in some AID also promising efficacy. However, the role of ECP in AID therapy is not established as most published studies are retrospective with limited number of patients and the trials are small or poorly standardized. The available data support future investigations of ECP as a therapeutic modality for the treatment of AID in well‐designed prospective clinical studies. J. Clin. Apheresis 30:224–237, 2015. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.Keywords
This publication has 121 references indexed in Scilit:
- Apoptotic cell-based therapies against transplant rejection: role of recipient’s dendritic cellsApoptosis, 2010
- The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent diseaseClinical and Experimental Immunology, 2009
- Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell populationClinical and Experimental Immunology, 2009
- Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes childrenClinical and Experimental Immunology, 2008
- A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisJournal of the American Academy of Dermatology, 2006
- SLE—a disease of clearance deficiency?Rheumatology, 2005
- Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)Journal of the American Academy of Dermatology, 1999
- Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresisJournal of the American Academy of Dermatology, 1993
- Pemphigus vulgaris treated with photopheresisJournal of the American Academy of Dermatology, 1992
- Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observationsJournal of the American Academy of Dermatology, 1990